越南双氢青蒿素/哌喹治疗恶性疟原虫疟疾的治疗失败情况
Treatment Failure of Dihydroartemisinin/Piperaquine for Plasmodium falciparum Malaria, Vietnam.
作者信息
Phuc Bui Quang, Rasmussen Charlotte, Duong Tran Thanh, Dong Le Than, Loi Mai Anh, Ménard Didier, Tarning Joel, Bustos Dorina, Ringwald Pascal, Galappaththy Gawrie Loku, Thieu Nguyen Quang
出版信息
Emerg Infect Dis. 2017 Apr;23(4):715-717. doi: 10.3201/eid2304.161872.
Abstract
We conducted a study in Binh Phuoc, Vietnam, in 2015 on the therapeutic efficacy of dihydroartemisinin/piperaquine for Plasmodium falciparum malaria. A high number of treatment failures (14/40) was found, and piperaquine resistance in Vietnam was confirmed. A change in the malaria treatment policy for Vietnam is in process.
摘要
2015年，我们在越南平阳省开展了一项关于双氢青蒿素/哌喹治疗恶性疟疗效的研究。结果发现大量治疗失败病例（14/40），证实越南存在哌喹耐药性。越南正在对疟疾治疗政策进行调整。
相似文献
1
Treatment Failure of Dihydroartemisinin/Piperaquine for Plasmodium falciparum Malaria, Vietnam.越南双氢青蒿素/哌喹治疗恶性疟原虫疟疾的治疗失败情况
Emerg Infect Dis. 2017 Apr;23(4):715-717. doi: 10.3201/eid2304.161872.
2
Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study.中医疗法治疗失败的决定因素：柬埔寨、泰国和越南间日疟原虫疟疾的前瞻性临床、药理学和遗传学研究。
Lancet Infect Dis. 2019 Sep;19(9):952-961. doi: 10.1016/S1473-3099(19)30391-3. Epub 2019 Jul 22.
3
Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin-piperaquine in the south of Vietnam.越南南部恶性疟原虫对双氢青蒿素-哌喹敏感性的迅速下降。
Malar J. 2017 Jan 13;16(1):27. doi: 10.1186/s12936-017-1680-8.
4
Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial.双氢青蒿素-哌喹治疗越南耐多药恶性疟原虫疟疾：随机临床试验
Lancet. 2004 Jan 3;363(9402):18-22. doi: 10.1016/s0140-6736(03)15163-x.
5
Evaluation of Dihydroartemisinin-Piperaquine Efficacy and Molecular Markers in Uncomplicated Falciparum Patients: A Study across Binh Phuoc and Dak Nong, Vietnam.评价双氢青蒿素-哌喹在无并发症恶性疟患者中的疗效及分子标志物：一项在越南平定省和得农省的研究。
Medicina (Kaunas). 2024 Jun 20;60(6):1013. doi: 10.3390/medicina60061013.
6
Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study.柬埔寨三突变（包括kelch13 C580Y）导致双氢青蒿素-哌喹耐药：一项观察性队列研究。
Lancet Infect Dis. 2015 Jun;15(6):683-91. doi: 10.1016/S1473-3099(15)70049-6. Epub 2015 Apr 12.
7
Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax to chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central Vietnam.越南中南部宁顺省福川乡恶性疟原虫对青蒿素类药物的敏感性和间日疟原虫对氯喹的敏感性。
Malar J. 2019 Jan 17;18(1):10. doi: 10.1186/s12936-019-2640-2.
8
Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison.双氢青蒿素-哌喹与青蒿琥酯-甲氟喹治疗恶性疟的疗效与效果：一项开放标签随机对照研究
Lancet. 2006 Jun 24;367(9528):2075-85. doi: 10.1016/S0140-6736(06)68931-9.
9
Efficacy of dihydroartemisinin/piperaquine and artesunate monotherapy for the treatment of uncomplicated Plasmodium falciparum malaria in Central Vietnam.中越地区二氢青蒿素/哌喹与青蒿琥酯单药治疗无并发症恶性疟原虫疟疾的疗效。
J Antimicrob Chemother. 2020 Aug 1;75(8):2272-2281. doi: 10.1093/jac/dkaa172.
10
Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study.柬埔寨恶性疟原虫疟疾中双氢青蒿素-哌喹耐药性：一项多地点前瞻性队列研究。
Lancet Infect Dis. 2016 Mar;16(3):357-65. doi: 10.1016/S1473-3099(15)00487-9. Epub 2016 Jan 8.
引用本文的文献
1
Investigating the relationship between mutations and response to artemisinin-based treatment for uncomplicated falciparum malaria: a protocol for a systematic review and individual patient data meta-analysis.探究单纯性恶性疟原虫疟疾中基因突变与基于青蒿素治疗反应之间的关系：一项系统评价和个体患者数据荟萃分析方案
BMJ Open. 2025 Jul 8;15(7):e100251. doi: 10.1136/bmjopen-2025-100251.
2
transcription factor AP2-06B is mutated at high frequency in Southeast Asia but does not associate with drug resistance.转录因子AP2-06B在东南亚地区高频突变，但与耐药性无关。
Front Cell Infect Microbiol. 2025 Jan 6;14:1521152. doi: 10.3389/fcimb.2024.1521152. eCollection 2024.
3
Mapping Antimalarial Drug Resistance in Mozambique: A Systematic Review of Genetic Markers Post-ACT Implementation.莫桑比克抗疟药物耐药性图谱：ACT实施后遗传标记的系统评价
Int J Mol Sci. 2024 Dec 20;25(24):13645. doi: 10.3390/ijms252413645.
4
Rapid detection of mutations in the suspected piperaquine resistance gene E415G-exo in Plasmodium falciparum exonuclease via AS‒PCR and RAA with CRISPR/Cas12a.通过AS-PCR和带有CRISPR/Cas12a的RAA快速检测恶性疟原虫核酸外切酶中疑似哌喹抗性基因E415G-exo的突变
Int J Parasitol Drugs Drug Resist. 2024 Dec;26:100568. doi: 10.1016/j.ijpddr.2024.100568. Epub 2024 Oct 28.
5
Evaluation of Dihydroartemisinin-Piperaquine Efficacy and Molecular Markers in Uncomplicated Falciparum Patients: A Study across Binh Phuoc and Dak Nong, Vietnam.评价双氢青蒿素-哌喹在无并发症恶性疟患者中的疗效及分子标志物：一项在越南平定省和得农省的研究。
Medicina (Kaunas). 2024 Jun 20;60(6):1013. doi: 10.3390/medicina60061013.
6
Antimalarial resistance risk in Mozambique detected by a novel quadruplex droplet digital PCR assay.新型四重液滴数字 PCR 检测法在莫桑比克发现抗疟药物耐药风险。
Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0034624. doi: 10.1128/aac.00346-24. Epub 2024 May 21.
7
Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine and prevalence of molecular markers of anti-malarial drug resistance in children in Togo in 2021.2021 年多哥儿童青蒿琥酯-咯萘啶和双氢青蒿素-哌喹的疗效和抗疟药物耐药性分子标志物的流行情况。
Malar J. 2024 Apr 3;23(1):92. doi: 10.1186/s12936-024-04922-1.
8
Emergence, transmission dynamics and mechanisms of artemisinin partial resistance in malaria parasites in Africa.非洲青蒿素部分耐药疟原虫的出现、传播动态和机制。
Nat Rev Microbiol. 2024 Jun;22(6):373-384. doi: 10.1038/s41579-024-01008-2. Epub 2024 Feb 6.
9
Exploring the feasibility of introducing triple artemisinin-based combination therapy in the malaria treatment policy in Vietnam.探索在越南疟疾治疗政策中引入三药联合疗法的可行性。
Malar J. 2023 Oct 28;22(1):326. doi: 10.1186/s12936-023-04763-4.
10
Molecular surveillance of Plasmodium falciparum drug-resistance markers in Vietnam using multiplex amplicon sequencing (2000-2016).利用多重扩增子测序技术对越南地区恶性疟原虫耐药相关分子标记物进行的监测（2000-2016 年）。
Sci Rep. 2023 Aug 25;13(1):13948. doi: 10.1038/s41598-023-40935-7.
本文引用的文献
1
A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study.耐哌喹恶性疟原虫疟疾的替代标志物：一项表型-基因型关联研究。
Lancet Infect Dis. 2017 Feb;17(2):174-183. doi: 10.1016/S1473-3099(16)30415-7. Epub 2016 Nov 3.
2
A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms.恶性疟原虫K13螺旋桨多态性的全球地图。
N Engl J Med. 2016 Jun 23;374(25):2453-64. doi: 10.1056/NEJMoa1513137.
3
Evidence of Plasmodium falciparum Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical Assessment.柬埔寨西部恶性疟原虫对青蒿素和哌喹多重耐药的证据：双氢青蒿素 - 哌喹开放标签多中心临床评估
Antimicrob Agents Chemother. 2015 Aug;59(8):4719-26. doi: 10.1128/AAC.00835-15. Epub 2015 May 26.
4
A molecular marker of artemisinin-resistant Plasmodium falciparum malaria.青蒿素耐药恶性疟原虫的一个分子标记。
Nature. 2014 Jan 2;505(7481):50-5. doi: 10.1038/nature12876. Epub 2013 Dec 18.
5
Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated falciparum malaria.比较无并发症恶性疟原虫疟疾患者的血浆、静脉血和毛细血管血中哌喹水平。
Eur J Clin Pharmacol. 2010 Jul;66(7):705-12. doi: 10.1007/s00228-010-0804-7. Epub 2010 Mar 19.
6
Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin.恶性疟原虫疟疾中pfmdr1拷贝数的减少会增加对甲氟喹、卤泛群、奎宁和青蒿素的易感性。
J Infect Dis. 2006 Aug 15;194(4):528-35. doi: 10.1086/507115. Epub 2006 Jul 11.
Zotero 插件